Chief Executive Officer

The organisation

Imagine a future where groundbreaking RNA technologies revolutionise healthcare, agriculture, and biosecurity in Australia. This vision is rapidly becoming a reality, spearheaded by RNA Australia, a dynamic joint venture established in March 2023 by the NSW Government and four leading NSW universities – including Macquarie University – along with the Australian National University (ANU). 

Their ambitious mission: to forge a national RNA research and development ecosystem, propelling Australia to the forefront of this transformative field. RNA Australia is not just about scientific discovery; it’s about translating that discovery into tangible benefits for the nation – from innovative therapies and life-saving vaccines to resilient crops and robust biosecurity measures. This pivotal moment demanded more than just a capable leader; it required a visionary – someone who could not only grasp the immense potential of RNA but also possess the strategic acumen to build an organisation from the ground up and navigate the complex landscape of research, commercialisation, and collaboration.  Construction is now underway at the RNA Research and Pilot Manufacturing Facility, strategically located at Macquarie University’s main campus, northwest of Sydney’s CBD, with completion scheduled for 2026.  This initiative builds upon existing NSW Government investments, including the NSW RNA Production & Research Network, the UNSW RNA Institute, and Australia’s first Viral Vector Manufacturing Facility at Westmead Health and Innovation District, with the state government committing $96 million to its construction.

The brief

RNA Australia stood at a critical juncture. To realise its ambitious goals, the newly formed company needed a CEO – not just an administrator, but a catalytic leader. The challenge was to find an individual with the rare blend of scientific understanding, commercialisation experience, and the gravitas to unite diverse stakeholders – universities, research institutes, industry partners, and investors – behind a shared vision. The primary objective was clear: appoint a visionary CEO capable of shaping RNA Australia’s strategy, deploying its cutting-edge resources and technology effectively, and ultimately maximising value for its members. This leader would be instrumental in overseeing the agreement with the commercial operator of the crucial RNA Pilot and Manufacturing Facility and working hand-in-hand with the Board to secure vital funding for future growth. The international search was on for a Sydney-based leader who could not only report to the Board but also inspire a nation.

The process

Brooker Consulting recognised the significance of this appointment. Invited to propose their approach, they understood that this wasn’t just about filling a role; it was about finding the architect of RNA Australia’s future. Their proposal emphasised a deep understanding of the life sciences sector and a proven track record in identifying exceptional executive talent. Winning the engagement, Brooker Consulting’s team, led by Lesley Lightfoot, immersed themselves in RNA Australia’s vision during a detailed in-person briefing with the Board. This collaborative session resulted in a precise candidate profile, outlining not just the required skills but also the desired leadership qualities and strategic mindset. A comprehensive search strategy was then meticulously crafted. This multi-pronged approach involved strategic placements in print media and targeted online advertising, leveraging Brooker Consulting’s extensive proprietary database, and activating their powerful network of referral partners and specialised industry contacts. The aim was clear: to cast a wide net and attract the highest caliber of global talent to this groundbreaking opportunity. The Brooker team’s diligent efforts generated significant interest, culminating in a compelling shortlist of candidates presented to the Selection Committee.

The outcome

The Selection Committee faced a welcome challenge: a truly outstanding field of candidates, with both local and international contenders , had been identified. This testament to the thoroughness of the search process made the final decision a rigorous one. From the initial impressive pool of eight, the final two candidates underwent thorough reference checks and insightful psychometric testing, providing a comprehensive understanding of their capabilities and potential. Ultimately, Laurent Contaut emerged as the chosen leader, poised to take the helm as the incoming CEO of RNA Australia. 

Mr. Contaut brings a wealth of experience, a seasoned leader with over 27 years navigating the intricate landscape of the pharmaceutical, biotechnology, medical technology, and artificial intelligence sectors across the globe. His diverse background, spanning start-ups to multinational corporations and academia, provides a unique and invaluable perspective. His strong foundation in manufacturing, coupled with his proactive engagement with the burgeoning RNA market in Europe, including expertise in GMP and GCP audits and the assessment of potential CDMO RNA facilities, underscores his deep understanding of the industry’s nuances. Laurent Contaut’s extensive experience and profound industry knowledge position him as an exceptional asset to lead RNA Australia into a future brimming with potential.